Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Fremanezumab in Migraine (HALO Extension)
NCT02638103Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Feb 2016
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of fremanezumab in chronic migraine, episodic migraine, sponsored by Teva Pharmaceutical Industries Ltd.. Started Feb 2016; status: completed.
02
Drugs
fremanezumab
03
Conditions
chronic migraineepisodic migraine
Beyond the preview
Go deeper on NCT02638103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02638103.